August 28, 2023
As the project partner, BLA congratulates BDGene on receiving the EU Orphan Drug Designations for the BD112 project in vivo gene editing therapy despite having only animal model data
As the project partner, BLA congratulates BDGene on receiving the EU Orphan Drug Designations for the BD112 project in vivo gene editing therapy despite having only animal model data Gaithersburg, MD (August 28, 2023) – BLA Regulatory, LLC, a full-service biopharma regulatory consultancy, congratulates Shanghai BDgene Therapeutics Co., Ltd. on receiving the Orphan Drug Designations […]
As the project partner, BLA congratulates BDGene on receiving the EU Orphan Drug Designations for the BD112 project in vivo gene editing therapy despite having only animal model data
As the project partner, BLA congratulates BDGene on receiving the EU Orphan Drug Designations for the BD112 project in vivo...
As the project partner, BLA congratulates Bendao Gene on receiving IND may proceed letter for BD111 project
As the project partner, BLA congratulates Bendao Gene on receiving IND may proceed letter for BD111 project Gaithersburg, MD (July...
As the project Supporter, BLA congratulates Lantern Pharma on receiving IND may proceed letter for LP-184 project
As the project Supporter, BLA congratulates Lantern Pharma on receiving IND may proceed letter for LP-184 project Gaithersburg, MD (June...